Circulating tumor cells for EGFR-TKI resistance in NSCLC patients; prospective, multicenter study

Circulating tumor cells for EGFR-TKI resistance in NSCLC patients; prospective, multicenter study - CTC for EGFR-TKI resistance in NSCLC

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015830

Enrollment

Registered

2014-12-03

Start date

2014-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung carcinoma with EGFR mutation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.NSCLC with EGFR mutation(Ex.18,19,21) 2.Kick off the Gefitinib 3.Having the detectable taget (>10mm) 4.Getting the informed consent

Exclusion criteria

Exclusion criteria: 1. HIV, HBV, HCV 2. History of Gefitinib, Erlotinib and crizotinib 3. Symptomatic brain metastasis 4. Presence of pulmonary fibrosis or interstitial pneumonia in chest CT 5. Active double cancer 6. Primary physician considered not to be suitable for the study.

Design outcomes

Primary

Measure	Time frame
The frequency of detecting T790M in CTC	—

Countries

Japan

Contacts

Public ContactNoriyuki Matsutani

Teikyo University School of Medicine Surgery

matsutan@med.teikyo-u.ac.jp03-3964-1231

Outcome results